ArticleMicrobial cell factories2026
Green metabolic engineering of Synechocystis sp. PCC 6803 for efficient production and sustainable extraction of β-cryptoxanthin and zeaxanthin.
Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundβ-xanthophylls, such as zeaxanthin and β-cryptoxanthin, display significant bioactive properties including anti-oxidant, anti-inflammation and anti-cancer activities. These properties spur their widespread use in food, animal feed, cosmetic and pharmaceutic sectors. However, commercial carotenoids are dominantly manufactured by chemical synthesis, posing environmental pollution. A minor fraction is sourced from plants and algae, a process often hampered by low yields and high costs. Consequently, microbial biosynthesis has emerged as a promising alternative for producing these high-value compounds.
resultsHere, we engineered the photosynthetic microorganism Synechocystis sp. PCC 6803 for efficient production of zeaxanthin and β-cryptoxanthin by two different strategies. In the first strategy, the gene crtO for echinenone biosynthesis and crtD involved in the myxoxanthophyll biosynthesis were inactivated, which increased the amount of zeaxanthin and β-cryptoxanthin by approximately 30% and 60%, respectively, reaching 1.3 mg/g DCW and 0.15 mg/g DCW in the double mutant ΔcrtO/crtD compared to wild type. The second strategy combined the replacement of the native β-carotene hydroxylase with a heterologous, high-efficiency plant enzyme and further improvement of precursor supply. The final strain oxBDI produced 5 mg/g DCW zeaxanthin and 1.5 mg/g DCW β-cryptoxanthin, fivefold and 18-fold higher than wild type, respectively, representing 80% of the total carotenoids produced. In addition, no significant difference was observed in the growth rate between transgenic strains and wild type under standard lab conditions, suggesting the applicability of this biotechnology strategy. Moreover, we explored the use of natural deep eutectic solvents (NADESs) as a green alternative for β-xanthophylls extraction from the engineered cyanobacteria using a simplified procedure. The NADES composed of food-grade menthol and acetic acid (1:1) achieved the highest efficiency, recovering 3.5 mg/g DCW of zeaxanthin and 1.2 mg/g DCW of β-cryptoxanthin, about 50% higher than the conventional solvent acetone, highlighting the strong potential of NADES as a green and safe solvent for carotenoid recovery from cyanobacteria.
conclusionsTaken together, our work reveals an efficient biotechnological strategy for production of zeaxanthin and β-cryptoxanthin, and a novel and efficient NADES-based method for eco-friendly recovery of high-value carotenoids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.